Change 5-day change 1-year change 3-year change Capi.($)
+28.60%-18.62% - - 16.15M
+2.07%+13.76%+65.44%+106.53% 70.1B
-0.87%+0.08%+36.96%+65.91% 54.93B
-4.50%-4.69%+2.82%+463.22% 28.89B
-1.09%-1.40%+46.72%+6.27% 23.9B
-0.67%+1.02%-18.32%-13.84% 23.3B
-0.59%+7.88%+40.87%-20.56% 18.77B
+0.35%+12.02%+257.19%+466.50% 18.41B
-1.43%-3.99%+19.46%+609.59% 16.1B
+0.46%-3.05%+31.49%+135.18% 12.48B
Average +2.23%+4.71%+53.63%+202.09% 29.65B
Weighted average by Cap. -0.36%+3.98%+50.95%+164.87%
Logo Opexa Therapeutics Inc
Acer Therapeutics Inc. is a pharmaceutical company, which is focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. The Company’s product pipeline includes OLPRUVA (sodium phenylbutyrate), ACER-801 (osanetant) and EDSIVO (celiprolol). OLPRUVA (sodium phenylbutyrate) for oral suspension is a formulation of sodium phenylbutyrate powder, for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Its ACER-801 (osanetant) is an investigational non-hormonal, neurokinin 3 receptor (NK3R) antagonist for the treatment of asomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer. Its EDSIVO (celiprolol) is a selective adrenergic modulator for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.
Employees
-